Celsee develops instruments and consumables for the isolation, detection and analysis of single cells. The company’s Genesis System allows scientists to isolate, analyze and interpret cellular behavior and collect cell-based information for improved results in single-cell cytometry, single-cell transcriptomics, single-cell multiomics, rare-cell enrichment and enumeration.
“We are pleased to have Celsee join Bio-Rad,” Bio-Rad president and CEO Norman Schwartz said in a news release. “Their innovative products and technologies will extend our reach into the rapidly growing world of precision medicine and single-cell analysis, both of which offer enhanced insight into disease, diagnosis and treatment.”
Bio-Rad earlier this week launched a blood-based immunoassay kit to help identify COVID-19 antibodies.